Dianthus Therapeutics (DNTH) Stock Forecast, Price Target & Predictions
DNTH Stock Forecast
Dianthus Therapeutics stock forecast is as follows: an average price target of $52.00 (represents a 125.16% upside from DNTH’s last price of $23.09) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.
DNTH Price Target
The average price target for Dianthus Therapeutics (DNTH) is $52.00 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $52.00 to $52.00. This represents a potential 125.16% upside from DNTH's last price of $23.09.
DNTH Analyst Ratings
According to 7 Wall Street analysts, Dianthus Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for DNTH stock is 0 'Strong Buy' (0.00%), 7 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Dianthus Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Nov 11, 2024 | Leland Gershell | Oppenheimer | $52.00 | $28.73 | 81.03% | 125.16% |
| Apr 18, 2024 | Steven Seedhouse | Raymond James | $51.00 | $24.15 | 111.18% | 120.83% |
The latest Dianthus Therapeutics stock forecast, released on Nov 11, 2024 by Leland Gershell from Oppenheimer, set a price target of $52.00, which represents a 81.03% increase from the stock price at the time of the forecast ($28.73), and a 125.16% increase from DNTH last price ($23.09).
Dianthus Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 2 |
| Avg Price Target | - | $52.00 | $51.50 |
| Last Closing Price | $23.09 | $23.09 | $23.09 |
| Upside/Downside | -100.00% | 125.16% | 122.99% |
In the current month, the average price target of Dianthus Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Dianthus Therapeutics's last price of $23.09. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Nov 11, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Oct 04, 2024 | Guggenheim | Buy | Buy | Hold |
| Oct 02, 2024 | Oppenheimer | Outperform | Initialise | |
| Sep 26, 2024 | H.C. Wainwright | Underperform | Underperform | Hold |
| Sep 26, 2024 | Wedbush | Buy | Buy | Hold |
| Aug 12, 2024 | Wedbush | Buy | Buy | Hold |
| Aug 12, 2024 | H.C. Wainwright | Underperform | Underperform | Hold |
| Jun 27, 2024 | Cantor Fitzgerald | Overweight | Initialise | |
| May 16, 2024 | H.C. Wainwright | Buy | Initialise | |
| Apr 18, 2024 | Raymond James | Outperform | Outperform | Hold |
| Nov 22, 2023 | Wedbush | Outperform | Initialise | |
| Dec 21, 2022 | BTIG | Buy | Buy | Hold |
| Jan 06, 2022 | Goldman Sachs | Buy | Upgrade |
Dianthus Therapeutics's last stock rating was published by Oppenheimer on Nov 11, 2024. The company gave DNTH a "Outperform" rating, the same as its previous rate.
Dianthus Therapeutics Financial Forecast
Dianthus Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $924.00K |
| Avg Forecast | $778.67K | $778.67K | $778.67K | $762.00K | $949.63K | $741.14K | $368.86K | $464.25K | $548.50K | $250.00K |
| High Forecast | $973.33K | $973.33K | $973.33K | $952.50K | $1.25M | $926.43K | $461.07K | $580.31K | $728.83K | $312.50K |
| Low Forecast | $584.00K | $584.00K | $584.00K | $571.50K | $774.69K | $555.86K | $276.64K | $348.19K | $225.41K | $187.50K |
| # Analysts | 1 | 1 | 1 | 4 | 6 | 3 | 1 | 1 | 3 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | - | 3.70% |
Dianthus Therapeutics's average Quarter revenue forecast for Dec 23 based on 3 analysts is $548.50K, with a low forecast of $225.41K, and a high forecast of $728.83K. DNTH's average Quarter revenue forecast represents a -40.64% decrease compared to the company's last Quarter revenue of $924.00K (Sep 23).
Dianthus Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 4 | 6 | 3 | 1 | 1 | 3 | 1 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-15.74M |
| Avg Forecast | $-155.73K | $-155.73K | $-155.73K | $-152.40K | $-189.92K | $-148.23K | $-73.77K | $-92.85K | $-109.70K | $-50.00K |
| High Forecast | $-116.80K | $-116.80K | $-116.80K | $-114.30K | $-154.94K | $-111.17K | $-55.33K | $-69.64K | $-45.08K | $-37.50K |
| Low Forecast | $-194.67K | $-194.67K | $-194.67K | $-190.50K | $-249.90K | $-185.28K | $-92.21K | $-116.06K | $-145.76K | $-62.50K |
| Surprise % | - | - | - | - | - | - | - | - | - | 314.87% |
undefined analysts predict DNTH's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Dianthus Therapeutics's previous annual EBITDA (undefined) of $NaN.
Dianthus Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 4 | 6 | 3 | 1 | 1 | 3 | 1 |
| Net Income | - | - | - | - | - | - | - | - | - | $-14.76M |
| Avg Forecast | $-31.08M | $-32.25M | $-31.95M | $-30.35M | $-28.98M | $-20.36M | $-18.67M | $-15.00M | $-32.18M | $-19.17M |
| High Forecast | $-20.98M | $-21.77M | $-21.57M | $-20.23M | $-19.55M | $-13.74M | $-12.60M | $-10.12M | $-30.15M | $-12.94M |
| Low Forecast | $-41.19M | $-42.74M | $-42.33M | $-39.49M | $-38.42M | $-26.97M | $-24.73M | $-19.87M | $-37.69M | $-25.40M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.77% |
Dianthus Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. DNTH's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Dianthus Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 4 | 6 | 3 | 1 | 1 | 3 | 1 |
| SG&A | - | - | - | - | - | - | - | - | - | $8.72M |
| Avg Forecast | $1.68M | $1.68M | $1.68M | $1.65M | $2.05M | $1.60M | $796.86K | $1.00M | $1.18M | $540.08K |
| High Forecast | $2.10M | $2.10M | $2.10M | $2.06M | $2.70M | $2.00M | $996.07K | $1.25M | $1.57M | $675.11K |
| Low Forecast | $1.26M | $1.26M | $1.26M | $1.23M | $1.67M | $1.20M | $597.64K | $752.20K | $486.96K | $405.06K |
| Surprise % | - | - | - | - | - | - | - | - | - | 16.15% |
Dianthus Therapeutics's average Quarter SG&A projection for Dec 23 is $1.18M, based on 3 Wall Street analysts, with a range of $486.96K to $1.57M. The forecast indicates a -86.42% fall compared to DNTH last annual SG&A of $8.72M (Sep 23).
Dianthus Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 4 | 6 | 3 | 1 | 1 | 3 | 1 |
| EPS | - | - | - | - | - | - | - | - | - | $-3.78 |
| Avg Forecast | $-0.91 | $-0.94 | $-0.93 | $-0.89 | $-0.85 | $-0.59 | $-0.55 | $-0.44 | $-0.94 | $-0.56 |
| High Forecast | $-0.61 | $-0.64 | $-0.63 | $-0.59 | $-0.57 | $-0.40 | $-0.37 | $-0.30 | $-0.88 | $-0.38 |
| Low Forecast | $-1.20 | $-1.25 | $-1.24 | $-1.15 | $-1.12 | $-0.79 | $-0.72 | $-0.58 | $-1.10 | $-0.74 |
| Surprise % | - | - | - | - | - | - | - | - | - | 6.75% |
According to undefined Wall Street analysts, Dianthus Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to DNTH previous annual EPS of $NaN (undefined).